Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vilazodone
Drug ID BADD_D02456
Description Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Indications and Usage Vilazodone is approved for treatment of major depressive disorder.[Label,A38477,A177622]
Marketing Status approved
ATC Code N06AX24
DrugBank ID DB06684
KEGG ID D09698
MeSH ID D000069503
PubChem ID 6918314
TTD Drug ID D0X6BV
NDC Product Code Not Available
UNII S239O2OOV3
Synonyms Vilazodone Hydrochloride | Hydrochloride, Vilazodone | 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) | Vilazodone HCl | HCl, Vilazodone | Viibryd | EMD 68843 | 68843, EMD | EMB-68843 | EMB 68843 | EMB68843 | Vilazodone | 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide
Chemical Information
Molecular Formula C26H27N5O2
CAS Registry Number 163521-12-8
SMILES C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia19.02.01.002; 17.15.03.0020.013640%
Irritability19.04.02.013; 08.01.03.0110.007635%
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.000703%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000319%Not Available
Libido decreased19.08.03.001; 21.03.02.0050.001086%
Loss of consciousness17.02.04.0040.000958%Not Available
Mania19.16.02.0020.004856%
Memory impairment17.03.02.003; 19.20.01.0030.002651%
Middle insomnia19.02.01.003; 17.15.03.0030.000319%Not Available
Migraine17.14.02.001; 24.03.05.0030.001725%Not Available
Mood altered19.04.02.0070.000703%Not Available
Mood swings19.04.03.0010.002172%Not Available
Movement disorder17.01.02.0100.000799%Not Available
Muscle spasms15.05.03.0040.004600%
Muscle twitching15.05.03.0050.003354%Not Available
Nausea07.01.07.0010.020732%
Night sweats23.02.03.006; 08.01.03.0310.001086%Not Available
Nightmare19.02.03.0030.008114%Not Available
Oedema14.05.06.010; 08.01.07.0060.000862%Not Available
Palpitations02.11.04.0120.004057%
Pancreatitis07.18.01.0010.000799%
Panic attack19.06.04.0010.001022%Not Available
Paraesthesia23.03.03.094; 17.02.06.0050.016771%
Paranoia19.05.01.0050.001725%Not Available
Pollakiuria20.02.02.0070.001086%
Pruritus23.03.12.0010.008561%
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.000703%Not Available
Rash pruritic23.03.13.0300.000703%Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.000319%
Restlessness19.11.02.002; 17.02.05.0210.001246%
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages